50 results on '"Tomblyn, Marcie"'
Search Results
2. A Review of Cellular Therapies for Chronic Lymphocytic Leukemia
3. Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation
4. Phase II Study of CD4+-Guided Pentostatin Lymphodepletion and Pharmacokinetically Targeted Busulfan as Conditioning for Hematopoietic Cell Allografting
5. Maximally Tolerated Busulfan Systemic Exposure in Combination with Fludarabine as Conditioning before Allogeneic Hematopoietic Cell Transplantation
6. ATG Prevents Severe Acute Graft-versus-Host Disease in Mismatched Unrelated Donor Hematopoietic Cell Transplantation
7. Reduced-Intensity Conditioning Followed by Related Allografts in Hematologic Malignancies: Long-Term Outcomes Most Successful in Indolent and Aggressive Non-Hodgkin Lymphomas
8. Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond First Complete Response or First Partial Response
9. An International Comparison of Current Strategies to Prevent Herpesvirus and Fungal Infections in Hematopoietic Cell Transplant Recipients
10. Decreased Infections in Recipients of Unrelated Donor Hematopoietic Cell Transplantation from Donors with an Activating KIR Genotype
11. Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective
12. Allogeneic Hematopoietic Cell Transplantation in Human Immunodeficiency Virus–Positive Patients with Hematologic Disorders: A Report from the Center for International Blood and Marrow Transplant Research
13. Promising Progression-Free Survival for Patients Low and Intermediate Grade Lymphoid Malignancies after Nonmyeloablative Umbilical Cord Blood Transplantation
14. Reduced-Intensity Allogeneic Transplant in Patients Older Than 55 Years: Unrelated Umbilical Cord Blood Is Safe and Effective for Patients without a Matched Related Donor
15. Similar and Promising Outcomes in Lymphoma Patients Treated with Myeloablative or Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation
16. New developments in antibody therapy for acute myeloid leukemia
17. Pre-Transplant Azacitidine and Allogeneic Hematopoietic Cell Transplant (HCT) Outcomes of One Hundred Fifty-Nine Patients up to Age Seventy-Five with Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
18. High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation Early during the Course of Disease Appears to Improve Outcomes of Patients T Cell Non-Hodgkin Lymphoma: Results of a Single-Institution Experience
19. Cibmtr Retrospective Analysis Reveals Incidence, Mortality, and Timing of Pneumocystis Jiroveci Pneumonia (PCP) after Hematopoietic Stem Cell Transplantation (HSCT)
20. Comparison of Infection Rates Among Acute Leukemia Patients in Remission Receiving Alternative Donor Hematopoietic Cell Transplantation
21. Related PBSC Donors Age >60 Have High Rates of Baseline and Donation-Related Pain and Slow Recovery: First Report from the Related Donor Safety Study (RDSafe)
22. A Phase I/II Trial Evaluating The Use Of a Histone Deacetylase Inhibitor Panobinostat (LBH589) In Addition To Glucocorticoids In Patients With Acute Graft-Versus-Host Disease
23. Evaluation Of Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes Of One Hundred Thirty-Two Patients With Myelodysplastic Syndrome (MDS) Or Chronic Myelomonocytic Leukemia (CMML) Up To Age Seventy-Five and The Effect Of Pre-Transplant 5-Azacitidine
24. A Phase I/II Trial Evaluating the Use of a Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients with Acute Graft Versus Host Disease
25. Assessment of a Disease Risk Index in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Fludarabine and Pharmacokinetically Dose-Targeted Intravenous Busulfan: Effect On Overall and Progression-Free Survival
26. Development of a Flexible, Functional Hematopoietic Cell Transplant (HCT) Database, BRAIN
27. Incidence of Pneumocystis Jirovecii Infection and Duration of Prophylaxis After Allogeneic Stem Cell Transplantation
28. Increased Number of Prior Therapies and/or Use of Mismatched Unrelated Donors Adversely Affect Allogeneic Hematopoietic Cell Transplantation (alloHCT) Outcomes in Relapsed/Refractory Hodgkin Lymphoma (HL)
29. Phase I/II Multicenter Clinical Trial of Lenalidomide Maintenance After Allogeneic Hematopoietic Cell Transplant (alloHCT) in Patients with High Risk (HR) Multiple Myeloma (MM)
30. Results of a Prospective Multi-Center Myeloablative Double-Unit Cord Blood Transplantation Trial in Adult Patients With Acute Leukemia and Myelodysplasia (submitted on behalf of the RCI BMT 05-DCB Protocol Team)
31. Outcomes of Allogeneic HSCT for Patients with Hematologic Malignancies (AML, ALL, MDS, CML) with and without Pre-Existing Fungal Infections: A CIBMTR Study
32. Long Term Followup of Bystander Vaccine Therapy in Mantle Cell Lymphoma (MCL),
33. Phase II Study of a Novel Reduced Toxicity Preparative Regimen for Hematopoietic Cell Allografting Combining Pentostatin (Nipent) and Targeted Doses of Intravenous Busulfan (Busulfex) with or without Rituximab (PB±R) Using a Novel Principle of CD4-Guided Immune Suppression
34. Fludarabine and Targeted Busulfan Is Safe and Effective Conditioning Before Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Lymphoblastic Leukemia in First Remission
35. Randomized Phase III Trial of 131iodine-Tositumomab (Bexxar)/Carmustine, Etoposide, Cytarabine, Melphalan (BEAM) Vs. Rituximab/BEAM and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL): No Difference in Progression-Free (PFS) or Overall Survival (OS)
36. Sirolimus/Tacrolimus Facilitates Preferential Recovery of Regulatory T Cells (Treg) After Allogeneic Hematopoietic Cell Transplantation (HCT), and Is More Effective Than Methotrexate/Tacrolimus in Preventing Grade II-IV Acute Graft Vs. Host Disease (GVHD) and Moderate to Severe Chronic Gvhd
37. Comparison of Two Mycophenolate Mofetil Dosing Regimens Following Hematopoietic Cell Transplantation (HCT).
38. Decreased Infections in Recipients of Unrelated Donor (URD Hematopoietic Cell Transplantation (HCT) from Donors with An Activating KIR B Genotype (B/x)
39. Pharmacogenetics of Mycophenolate Mofetil in Patients Undergoing Hematopoietic Cell Transplantation (HCT).
40. Encouraging Results of Reduced Intensity Conditioning (RIC) Umbilical Cord Blood (UCB) Transplantation for the Treatment of Advanced Lymphoid Malignancies.
41. A Phase 3 Randomized, Historically-Controlled Clinical Trial Investigating the Use of Defibrotide in the Treatment of Severe Veno-Occlusive Disease Post-SCT: A Novel Approach to the Validation of a Promising New Drug for the Treatment of a Life Threatening Disease.
42. Reduced Intensity Allogeneic Transplant in Patients Older Than 55 Years: Unrelated Umbilical Cord Blood Is Safe and Effective for Patients without a Matched Related Donor.
43. 29: A Novel Triple Umbilical Cord Blood Transplant (UCBT) Strategy to Promote NK Cell Immunotherapy (Unit 1) with a Fully Ablative Preparative Regimen Followed By a Double UCBT in Patients with Refractory AML
44. A Novel Triple Umbilical Cord Blood Transplant (UCBT) Strategy To Promote NK Cell Immunotherapy (Unit 1) with a Fully Ablative Preparative Regimen Followed by a Double UCBT in Patients with Refractory AML.
45. Promising Progression Free and Overall Survival Using a Novel (CY/FLU/TBI) Reduced-Intensity Conditioning (RIC) Regimen for Allogeneic Sibling Stem Cell Transplantation (SCT).
46. Allogeneic Hematopoietic Stem Cell Transplantation in HIV-Positive Patients with Malignant and Non-Malignant Disorders: A Report from the Center for International Blood and Marrow Transplant Research (CIBMTR).
47. 10: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Treatment of Acute Lymphocytic Leukemia (ALL) in 126 Adults: Impact of Donor Source on Leukemia Free Survival (LFS)
48. Immunotherapy of EBV Post Solid Organ Transplantation Lymphoproliferative Disease with Genetically Engineered Haploidentical T Cells.
49. Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Treatment of Acute Lymphocytic Leukemia (ALL) in 126 Adults: Impact of Donor Source on Leukemia Free Survival (LFS).
50. Prolonged Remissions with Autologous and Allogeneic Stem Cell Transplantation for Burkitt's Lymphoma: Long Term Follow-Up at a Single Institution.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.